Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$1.64
-2.4%
$1.24
$0.80
$3.08
$67.37M-0.9819,269 shs75,188 shs
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
$3.98
+4.7%
$3.97
$2.74
$7.28
$72.79M0.5916,797 shs11,621 shs
HSTC
HST Global
$0.30
$0.66
$0.23
$1.10
$17.39M-1.24175 shsN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.14
+3.6%
$1.18
$0.83
$5.39
$70.62M1.13583,545 shs617,094 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+16.78%+57.87%+68.81%-34.17%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
0.00%+24.81%-22.77%+12.11%+25.06%
HSTC
HST Global
0.00%0.00%-63.73%-63.73%-70.78%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%+1.36%-17.41%+16.53%-61.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.2105 of 5 stars
3.53.00.00.00.01.70.0
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
1.8566 of 5 stars
3.53.00.00.00.61.70.0
HSTC
HST Global
N/AN/AN/AN/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.2128 of 5 stars
3.41.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
3.00
Buy$5.50235.37% Upside
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
3.00
Buy$25.00528.14% Upside
HSTC
HST Global
0.00
N/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00689.47% Upside

Current Analyst Ratings Breakdown

Latest HSTC, GNTA, ANEB, and PYXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $3.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/A$0.74 per shareN/A
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.37N/AN/A$2.03 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-90.11%-84.53%9/23/2025 (Estimated)
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
-$9.64MN/A0.00N/AN/AN/AN/AN/AN/A
HSTC
HST Global
-$150K-$0.02N/AN/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)

Latest HSTC, GNTA, ANEB, and PYXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/13/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.04+$0.01-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
25.29
25.29
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
N/A
6.89
6.89
HSTC
HST Global
N/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.75
7.75

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
15.13%
HSTC
HST Global
N/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
28.99%
HSTC
HST Global
65.82%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.08 million7.97 millionNot Optionable
Genenta Science S.p.A. Unsponsored ADR stock logo
GNTA
Genenta Science
718.29 million12.99 millionNot Optionable
HSTC
HST Global
157.77 million19.75 millionNot Optionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million55.38 millionOptionable

Recent News About These Companies

Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)
Pyxis Oncology (PYXS) Gets a Hold from William Blair

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.64 -0.04 (-2.38%)
As of 03:45 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Genenta Science stock logo

Genenta Science NASDAQ:GNTA

$3.98 +0.18 (+4.74%)
As of 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

HST Global OTCMKTS:HSTC

$0.30 0.00 (0.00%)
As of 07/3/2025

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.14 +0.04 (+3.64%)
As of 04:00 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.